Disc Medicine to Participate in SVB Securities Global Biopharma Conference
February 08 2023 - 4:00PM
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, announced today that John
Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc
Medicine, will participate in a fireside chat in a virtual format
at the SVB Securities Global Biopharma Conference on Thursday,
February 16, 2023 at 8:40 a.m. ET.
A live webcast of the fireside chat will be available through
the investor relations section of the Company's website at
ir.discmedicine.com and an archived replay will be available.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company
committed to discovering, developing, and commercializing novel
treatments for patients who suffer from serious hematologic
diseases. We are building a portfolio of innovative, first-in-class
therapeutic candidates that aim to address a wide spectrum of
hematologic diseases by targeting fundamental biological pathways
of red blood cell biology, specifically heme biosynthesis and iron
homeostasis. For more information, please visit
www.discmedicine.com.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Suzanne Messere Stern Investor
Relationssuzanne.messere@sternir.com
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Jul 2023 to Jul 2024